Daniel Chen
Partner & Co-Founder Genesis BioCapital
Seminars
Wednesday 14th October 2026
Innovating the A of ADC: Breaking Down Mechanisms, Learnings & Clinical Prospect of Multispecific ADCs
11:00 am
- Understanding the different avenues of innovation of masked and conditionally active ADCs to highlight ability to reduce on-target, off-tumor toxicity
- Breaking down the principles and advantages of bispecific ADC logic gates including AND gate EGFR-cMET ADCs
- Analyzing the maturing pipeline of multispecific ADCs to set the context of how antibody-led ADC innovation will translate to the clinic
Wednesday 14th October 2026
Innovating Antibody Targeting & Engineering to Improve ADC Therapeutic Properties & Unlock New Treatment Indications
